Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 6, 2015, Pages 715-719

  Mobs C ^a   Muller J ^a   Rudzio, A ^a   Pickert, J ^a   Blank, S ^b   Jakob, T ^c   Spillner, E ^d   Pfützner, Wolfgang ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

Allergen specific immunotherapy; Blocking antibodies; Enzyme linked immunosorbent facilitated antigen binding; IgG; Insect venom

Indexed keywords

ALLERGEN; BLOCKING ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G4; UNCLASSIFIED DRUG; VES V 5; WASP VENOM; ALLERGEN VES V 1; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INSECT PROTEIN; VES V 5 ALLERGEN;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGY; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COMPLEX FORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSORBENT FACILITATED ANTIGEN BINDING ASSAY; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; WASP VENOM ALLERGY; ADULT; AGED; DESENSITIZATION; FEMALE; HYPERSENSITIVITY, IMMEDIATE; IMMUNOLOGY; MALE; MIDDLE AGED; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ALLERGENS; ANTIBODIES, BLOCKING; DESENSITIZATION, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INSECT PROTEINS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; WASP VENOMS; YOUNG ADULT;

EID: 84929887868     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12606     Document Type: Article

References (18)

1. Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, et al., Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012; 10: CD008838.
2. Golden DB,. Long-term outcome after venom immunotherapy. Curr Opin Allergy Clin Immunol 2010; 10: 337-341.
3. Lerch E, Müller UR,. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998; 101: 606-612.
4. Reisman RE,. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993; 92: 831-836.
5. Möbs C, Ipsen H, Mayer L, Slotosch C, Petersen A, Würtzen PA, et al., Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies. J Allergy Clin Immunol 2012; 130: 1108-1116.
6. Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I, et al., Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012; 67: 217-226.
7. Ferrante A, Mocatta F, Goh DH,. Changes in IgG and IgE antibody levels to bee venom during immunotherapy. Int Arch Allergy Appl Immunol 1986; 81: 284-287.
8. Urbanek R, Kemeny DM, Richards D,. Sub-class of IgG anti-bee venom antibody produced during bee venom immunotherapy and its relationship to long-term protection from bee stings and following termination of venom immunotherapy. Clin Allergy 1986; 16: 317-322.
9. Varga EM, Francis JN, Zach MS, Klunker S, Aberer W, Durham SR,. Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children. Clin Exp Allergy 2009; 39: 1353-1357.
10. Ring J, Messmer K,. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1: 466-469.
11. Rueff F, Bergmann KC, Brockow K, Fuchs T, Grubl A, Jung K, et al., [Skin tests for diagnostics of allergic immediate-type reactions. Guideline of the German Society for Allergology and Clinical Immunology]. Pneumologie 2011; 65: 484-495.
12. Shamji MH, Francis JN, Wurtzen PA, Lund K, Durham SR, Till SJ,. Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol 2013; 132: 1003-1005.
13. Geroldinger-Simic M, Zelniker T, Aberer W, Ebner C, Egger C, Greiderer A, et al., Birch pollen-related food allergy: clinical aspects and the role of allergen-specific IgE and IgG4 antibodies. J Allergy Clin Immunol 2011; 127: 616-622.
14. Würtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H,. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy 2008; 38: 1290-1301.
15. Shamji MH, Wilcock LK, Wachholz PA, Dearman RJ, Kimber I, Wurtzen PA, et al., The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006; 317: 71-79.
16. van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, et al., Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163: 2944-2952.
17. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM,. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol 1998; 101: 298-305.
18. Goldberg A, Confino-Cohen R,. Effectiveness of maintenance bee venom immunotherapy administered at 6-month intervals. Ann Allergy Asthma Immunol 2007; 99: 352-357.